Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
Alise Carlson, Moein Amin, Jeffrey A. Cohen
Drugs (2024) Vol. 84, Iss. 3, pp. 285-304
Open Access | Times Cited: 16

Showing 16 citing articles:

Urgent Issues in Multiple Sclerosis
Methma Udawatta, Marcelo Matiello
Medical Clinics of North America (2025)
Closed Access
Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
Hui Chen
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Efficacy and Safety of Ofatumumab Treatment for Anti‐NMDA Receptor Autoimmune Encephalitis (OFF‐AE): A Prospective, Multicenter Cohort Study
Kundian Guo, Fuhua Peng, Jia Liu, et al.
Annals of Neurology (2025)
Closed Access
Case Report: Efficacy of ofatumumab in refractory anti-NMDAR encephalitis: case series and literature review
Min Deng, Jing Xiong, Dan Hu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Multiple sclerosis in china: the current state of diagnosis and management
Dongmei Jia, Fu‐Dong Shi, Wei Jiang
Current Opinion in Neurology (2025)
Closed Access
Choosing initial MS therapy; personal, disease, and medication factors
Bruce A. Cohen
Neurotherapeutics (2025), pp. e00582-e00582
Open Access
Plasma Exchange vs. Immunoadsorption: Effects on Immunological Markers and Predictive Value in Steroid-Refractory MS Attacks
Ioannis Vardakas, Johannes Dorst, André Huss, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2025) Vol. 11, Iss. 2
Open Access
Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database
Raffaella Di Napoli, Nunzia Balzano, Concetta Rafaniello, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 8
Open Access | Times Cited: 2
Uveitis und multiple Sklerose
Nicole Stübiger, Klemens Ruprecht, Uwe Pleyer
Deleted Journal (2024) Vol. 121, Iss. 8, pp. 665-678
Closed Access | Times Cited: 1
Anti-CD20 Therapies for Pediatric-Onset Multiple Sclerosis: a systematic review
Masoud Etemadifar, Hosein Nouri, Nahad Sedaghat, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 91, pp. 105849-105849
Closed Access
Pre-analytical stability of ocrelizumab in serum after delayed centrifugation of whole blood
Jeongsup Shim, Montserrat Carrasco‐Triguero, Saloumeh K Fischer
AAPS Open (2024) Vol. 10, Iss. 1
Open Access
Fractal Dimension Analysis of the Tumor Microenvironment in Cutaneous Squamous Cell Carcinoma: Insights into Angiogenesis and Immune Cell Infiltration
Alexandra Buruiană, Mircea-Sebastian Șerbănescu, Bogdan Pop, et al.
Fractal and Fractional (2024) Vol. 8, Iss. 10, pp. 600-600
Open Access
The origin of human CD20+ T cells: a stolen identity?
Marina Rode von Essen, Lisbeth Egelykke Stolpe, Helle Bach Søndergaard, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Inhibiting CD40 Ligand in Multiple Sclerosis: A Review of Emerging Therapeutic Potential
Patrick Vermersch, David H. Wagner, Lennart T. Mars, et al.
Current Treatment Options in Neurology (2024) Vol. 27, Iss. 1
Open Access
Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials
Eoin Moloney, Atefeh Mashayekhi, Sakshi Sharma, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access
Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy
Zeinab Awada, Natasha Hameed, Asaff Harel
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 5985-5996
Open Access
Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective
Mark Kačar, Adam Al‐Hakim, Sinisa Savic
BioDrugs (2024)
Closed Access
Page 1

Scroll to top